Characteristic | OVERALL | CASE Rehospitalized | CONTROL Not rehospitalized during same time interval from index hospital discharge |
---|---|---|---|
N = 3227 | N = 1674 | N = 1674 | |
β-Blocker Intensification in Prior 30-Days | 39 (2.3%) | 27 (1.6%) | |
Matching variables | |||
Age, years, median (IQR) | 76.1 (67.2-83.5) | 75.8 (68.6-82.9) | 75.8 (68.5-82.9) |
Female Gender | 1715 (53.2%) | 895 (53.5%) | 895 (53.5%) |
Year of Index Hospitalization | |||
2001 | 409 (12.7%) | 229 (13.7%) | 229 (13.7%) |
2002 | 393 (12.2%) | 220 (13.1%) | 220 (13.1%) |
2003 | 362 (11.2%) | 222 (13.3%) | 222 (13.3%) |
2004 | 401 (12.4%) | 247 (14.8%) | 247 (14.8%) |
2005 | 438 (13.6%) | 261 (15.6%) | 261 (15.6%) |
2006 | 354 (11.0%) | 186 (11.1%) | 186 (11.1%) |
2007 | 358 (11.1%) | 176 (10.5%) | 176 (10.5%) |
2008 | 344 (10.7%) | 123 (7.3%) | 123 (7.3%) |
2009 | 168 (5.2%) | 10 (0.6%) | 10 (0.6%) |
LVSD at index hosp | 1108 (37.0%) | 574 (34.3%) | 574 (34.3%) |
Covariates | |||
History of Myocardial Infarction | 427 (13.2%) | 245 (14.6%) | 182 (10.9%) |
History of Atrial Fibrillation | 1422 (44.1%) | 759 (45.3%) | 748 (44.7%) |
History of Diabetes | 1457 (45.1%) | 836 (49.9%) | 732 (43.7%) |
History of COPD | 1230 (38.1%) | 707 (42.2%) | 614 (36.7%) |
History of Chronic Liver Disease | 67 (2.1%) | 33 (2.0%) | 25 (1.5%) |
Systolic BP preceding readmission or matched time period, mmHg, median (IQR) | 122 (110–139) | 122 (110–138) | 124 (110–140) |
Diastolic BP preceding readmission or matched time period, mmHg, median (IQR) | 68 (60–78) | 68 (60–78) | 70 (60–78) |
Heart rate preceding readmission or matched control time period, bpm, median (IQR) | 54 (42–68) | 53 (42–67) | 55 (44–66) |
CrCl preceding readmission or matched control time period, mL/min/1.73 m2, median (IQR) | 50.2 (34.9-65.6) | 49.8 (34.3-65.1) | 55.2 (41.0-71.2) |
β-Blocker Use (at anytime in follow up) | |||
Atenolol | 551 (17.1%) | 307 (18.3%) | 334 (20.0%) |
Carvedilol | 222 (6.9%) | 113 (6.8%) | 104 (6.2%) |
Metoprolol Succinate | 526 (16.3%) | 266 (15.9%) | 261 (15.6%) |
Metoprolol Tartrate | 1079 (33.4%) | 634 (37.9%) | 606 (36.2%) |
Other β-Blocker | 57 (1.8%) | 31 (1.9%) | 38 (2.3%) |
No β-Blocker | 792 (24.54%) | 322 (19.2%) | 331 (19.8%) |
Switch β-Blocker Type During Follow Up | 538 (2.1%) | 343 (25.4%) | 311 (23.2%) |